PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

(2016) Takehito Shukuya et al.   Journal of Thoracic Oncology

Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

(2016) Zhong-Yi Dong et al.   TUMOR BIOLOGY

Targetable genetic features of primary testicular and primary central nervous system lymphomas

(2015) B. Chapuy et al.   BLOOD

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

(2015) C. Copie-Bergman et al.   BLOOD

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

MYC/BCL6double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis

(2015) Shaoying Li et al.   HISTOPATHOLOGY

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy

(2015) François Bertucci et al.   Oncotarget

Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas

(2014) James R. Cook et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

(2014) Kamraan Z. Gill et al.   PLoS One

Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas

(2013) Anna Brunn et al.   ACTA NEUROPATHOLOGICA

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)

(2013) Anna Sophie Berghoff et al.   CLINICAL NEUROPATHOLOGY

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

(2011) J. Iqbal et al.   CLINICAL CANCER RESEARCH

LIM domain only 2 protein expression,LMO2germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era

(2011) James R. Cerhan et al.   LEUKEMIA & LYMPHOMA

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome

(2011) Shaoying Li et al.   MODERN PATHOLOGY

PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral Lymphadenitis

(2010) Chandra Krishnan et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma

(2010) Anastasios Chatzitolios et al.   ANNALS OF HEMATOLOGY

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas

(2008) K. Amara et al.   ANNALS OF ONCOLOGY

Del(6)(q22) andBCL6Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course

(2008) Francois M. Cady et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

(2008) James Rubenstein et al.   LEUKEMIA & LYMPHOMA

LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab

(2007) Yasodha Natkunam et al.   JOURNAL OF CLINICAL ONCOLOGY